Chief Medical Officer

Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website

ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025

Bristol Myers, SystImmune report global Phase 1 results of Iza-bren

Senior Clinical Research Associate

SystImmune is a leading and well-funded clinical-stage biopharmaceutical company specializing in developing innovative cancer treatments. The Senior Clinical Research Associate (CRA) will manage and oversee assigned clinical study sites, ensuring document collection, data quality, and patient safety in accordance with regulations and guidelines.

Sign up with Google

Sign in with Google